These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162 [TBL] [Abstract][Full Text] [Related]
8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
9. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Piccinelli M; Pini S; Bellantuono C; Wilkinson G Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913 [TBL] [Abstract][Full Text] [Related]
11. Sertraline and mental retardation with obsessive-compulsive disorder. Wiener K; Lamberti JS Am J Psychiatry; 1993 Aug; 150(8):1270. PubMed ID: 8328577 [No Abstract] [Full Text] [Related]
12. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Chouinard G Int Clin Psychopharmacol; 1992 Oct; 7 Suppl 2():37-41. PubMed ID: 1484177 [TBL] [Abstract][Full Text] [Related]
13. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible? Todorov C; Freeston MH; Borgeat F Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882 [TBL] [Abstract][Full Text] [Related]